Raelipskie Partnership Boosts Stock Position in Novo Nordisk A/S (NYSE:NVO)

Raelipskie Partnership raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 23.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 15,618 shares of the company’s stock after purchasing an additional 3,000 shares during the period. Raelipskie Partnership’s holdings in Novo Nordisk A/S were worth $1,343,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. WCM Investment Management LLC raised its holdings in Novo Nordisk A/S by 1.0% during the fourth quarter. WCM Investment Management LLC now owns 4,031,124 shares of the company’s stock valued at $345,588,000 after acquiring an additional 40,475 shares during the period. Natixis Advisors LLC boosted its position in shares of Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares during the period. International Assets Investment Management LLC boosted its position in shares of Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after buying an additional 1,796,635 shares during the period. LPL Financial LLC boosted its position in shares of Novo Nordisk A/S by 3.6% during the third quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after buying an additional 47,496 shares during the period. Finally, DAVENPORT & Co LLC raised its stake in shares of Novo Nordisk A/S by 75.1% during the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after acquiring an additional 451,641 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 1.1 %

NVO stock opened at $77.94 on Monday. The firm has a 50-day moving average of $88.65 and a two-hundred day moving average of $109.54. Novo Nordisk A/S has a 12 month low of $77.82 and a 12 month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. The company has a market cap of $349.75 billion, a price-to-earnings ratio of 23.69, a PEG ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, analysts forecast that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 21.88%.

Analyst Ratings Changes

Several analysts have recently weighed in on NVO shares. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.